drugset
drugset / Trial / NCT06007222

Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial

NCT06007222 ↗

Phase 4 Recruiting 400 enrolled OCEAN-SHD Study Group
RandomizedParallel-groupOpen-labelTreatment

Summary

Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period. Non-antithrombotic group: No antithrombotic agents will be administered after randomization until the end of the study period.

Timeline

Start
2023-04-06
Primary completion
2026-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 100 mg —

Indications

aortic valve stenosis